Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells

Abstract

The current invention concerns a composition for treating trauma in a subject, where the composition includes isolated mesenchymal stem cells (MSCs), wherein the MSCs are tenogenic-induced and/or chondrogenic-induced, and where the trauma is tendon trauma, traumas of the ligaments, or trauma of cartilage.

1 . A composition for treating trauma in a subject, comprising:
 isolated mesenchymal stem cells (MSCs), wherein the MSCs are tenogenic-induced and/or chondrogenic-induced, and wherein the trauma is selected from tendon traumas, traumas of the ligaments, and trauma of cartilage.   
     
     
         2 . The composition according to  claim 1 , wherein the MSCs are derived from blood. 
     
     
         3 . The composition according to  claim 2 , wherein the blood is peripheral blood. 
     
     
         4 . The composition according to  claim 1 , wherein said MSCs are equine-derived. 
     
     
         5 . The composition according to  claim 1 , wherein said MSCs are allogenic MSCs. 
     
     
         6 . The composition according to  claim 1 , wherein the composition comprises between 1 and 10×10 6  cells/ml. 
     
     
         7 . The composition according to  claim 1 , further comprising platelet-rich plasma (PRP), hyaluronic acid and/or glycosaminoglycans. 
     
     
         8 . The composition according to  claim 1 , wherein the MSCs are suspended in a cell medium comprising a cryoprotectant. 
     
     
         9 . The composition according to  claim 8 , wherein the medium is Dulbecco's Modified Eagle's Medium Low Glucose (DMEM LG) 
     
     
         10 . The composition according to  claim 8 , wherein the cryoprotectant is dimethyl sulfoxide (DMSO). 
     
     
         11 . The composition according to  claim 1 , wherein the MSCs are tenogenic-induced and the trauma is tendon traumas and/or traumas of the ligaments. 
     
     
         12 . The composition according to  claim 11 , wherein said composition is administered to a subject by means of intra-lesional administration. 
     
     
         13 . The composition according to  claim 12 , wherein the subject is a horse and wherein the trauma is tendon trauma comprising a lesion of a superficial digital flexor tendon (SDFT). 
     
     
         14 . The composition according to  claim 12 , wherein the subject is a horse and wherein the trauma is ligament trauma comprising a lesion of a suspensory ligament of the horse or a lesion of an accessory ligament of a deep digital flexor tendon (ALDDFT) of the horse. 
     
     
         15 . The composition according to  claim 1 , wherein the MSCs are chondrogenic-induced and wherein the trauma is cartilage trauma. 
     
     
         16 . The composition according to  claim 15 , wherein the composition is administered by means of intra-articular administration. 
     
     
         17 . The composition according to  claim 15 , wherein said subject is a horse and wherein the cartilage trauma comprises lameness due to fetlock joint osteoarthritis. 
     
     
         18 . The composition according to  claim 11 , wherein said tenogenic-induced MSCs are induced in vitro towards tenogenesis by means of a cell medium comprising 5 ng/ml FGF-2. 
     
     
         19 . The composition according to  claim 15 , wherein said chondrogenic-induced MSCs are induced in vitro towards chondrogenesis by means of a cell medium comprising 4 ng/ml TGFβ3 and 120 ng/ml IGF-1.